

RINSHO HINYOKIKA

(JAPANESE JOURNAL OF CLINICAL UROLOGY)

Advisory Board : **Toyohei Machida MD, Akimi Ogawa MD, Masao Akimoto MD, Masaru Murai MD**

Editorial Board : **Kenjiro Kohri MD, Tomoaki Fujioka MD, Mototsugu Oya MD**

CONTENTS

Vol 66 No 1 January 2012

SPECIAL THEME : Guide for selection of molecular target drugs in advanced renal cell carcinoma patients

Cytokine therapy or molecular targeted therapy : which is optimal treatment for untreated patients with metastatic renal cell carcinoma who are classified as low- or intermediate-risk according to Memorial Sloan Kettering Cancer Center risk classification? —————	Nobuo Shinohara	11
Molecularly targeted therapy for untreated and poor risk patients with advanced renal cell carcinoma —————	Takeshi Ueda, et al	19
Which is the best molecular target drug for cytokine-refractory metastatic renal cell carcinoma? —————	Tomoharu Fukumori, et al	27
Targeted therapy to metastatic renal cell carcinoma : combination and sequential therapy —————	Yoshihiko Tomita	33
Is there a role for presurgical treatment for renal cell carcinoma? —————	Yasuhisa Fujii	43
Biomarkers in renal cell carcinoma : role in clinical practice —————	Ryuichi Mizuno, et al	51
Molecular target therapy for non-clear cell RCC : biological insight will lead to individualized therapy —————	Takeshi Kishida	59
Is there new molecular targeted drug for renal cell carcinoma? —————	Takuma Kato, et al	69
Targeted agents for RCC—the adverse effects and their management —————	Takeshi Yuasa, et al	77